2022.04.29
SHANGHAI, China and GAITHERSBURG, MD. , April 29, 2022 (PRNewswire) — I-Mab (“I-Mab” or the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company has filed its annual
2022.03.15
SHANGHAI and GAITHERSBURG, Md. , March 15, 2022 /PRNewswire/ -- I-Mab ( " I-Mab " or the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provides updates on the recent development
Displaying 1 - 10 of 14